Upadacitinib is metabolized predominantly by CYP3A4 and, to a lesser extent, by CYP2D6, and hepatic insufficiency and renal insufficiency have no clinically relevant effect on the concentration on it, which is significantly affected in the organism only by interactions with the other substrates of CYP3A4 [87]. The gene discussed is CYP3A4; the disease is Renal insufficiency.